Tirzepatide and Prader-Willi diabetes

A case report published in the journal Medicine on September 4, 2026 describes an adult woman with Prader-Willi syndrome (PWS) whose type 2 diabetes had resisted a five-drug combination, insulin, metformin, chiglitazar sodium, a GLP-1 receptor agonist, and an SGLT2 inhibitor, until her clinicians swapped the GLP-1 drug for tirzepatide. The switch brought what the authors call notable improvements in appetite, body weight, and glycemic control^[1]. This is one patient in a published report, not a trial, so the honest read is a lead for clinicians managing a rare, hard-to-treat combination, not proof that tirzepatide works for Prader-Willi syndrome generally.

What Prader-Willi syndrome is, and what made this case unusual

PWS is a genetic disorder caused by loss of function of paternally inherited genes in the 15q11.2-q13 region of chromosome 15, most often through a deletion, though maternal uniparental disomy and imprinting defects account for a smaller share of cases. Estimates of birth incidence range from roughly 1 in 8,290 to 1 in 30,000^[2]. The syndrome typically shows up in infancy as weak muscle tone and feeding difficulty severe enough to need a feeding tube, then shifts in early childhood to an intense, hard-to-control drive to eat that leads to severe obesity if food access is not tightly managed.

The patient in this report was diagnosed with PWS and diabetes together, in adulthood, though her history, hypotonia, developmental delay, intellectual disability, hyperphagia and morbid obesity since childhood, plus gonadal underdevelopment at puberty, matches the classic picture. Genetic testing found a deletion in the 15q11.2-q13.1 region, and DNA methylation analysis confirmed the diagnosis^[1]. About a quarter of adults with PWS develop type 2 diabetes, typically by around age 20^[2], so the diabetes itself was not surprising. What is notable is that the syndrome had gone unconfirmed until she was already an adult presenting with treatment-resistant blood sugar.

What changed when the treatment switched

According to the published abstract, the patient's initial combination of insulin, metformin, chiglitazar sodium (an oral diabetes drug), a glucagon-like peptide-1 (GLP-1) receptor agonist, and an SGLT2 inhibitor showed limited efficacy. Her clinicians then substituted the GLP-1 drug for tirzepatide, a dual GIP and GLP-1 receptor agonist, and the case report describes that substitution as producing improvements in appetite suppression, weight, and glycemic control^[1]. The published abstract does not give the specific dose, treatment duration, or the size of the change in HbA1c or body weight, so those numbers cannot be reported here without the full paper.

This is not the first attempt at a GLP-1-class drug in PWS. A 2022 systematic review in Clinical Endocrinology pooled ten studies covering 23 patients with PWS, ages 13 to 37, treated with either exenatide or liraglutide for 14 weeks to 4 years. Sixteen of the 23 also had type 2 diabetes. Ten patients improved on body mass index (by 1.5 to 16.0 kg/m2), 19 of 23 improved on HbA1c (by 0.3 to 7.5 percentage points), and every study that measured appetite reported better satiety, with no serious side effects reported^[3]. The reviewers were still cautious: they called the drugs promising but said the lack of well-designed studies limited any firm recommendation. The new case adds tirzepatide, a newer and more potent dual agonist, to that same short list.

What one case report cannot tell us

A single case has no comparison group, no blinding, and in this instance no full-text paper yet indexed for independent scrutiny of the raw numbers. The abstract's own conclusion is measured: the authors frame the case as a reminder to check for genetic syndromes in early-onset severe obesity with diabetes, and as pointing to tirzepatide's potential for PWS-associated metabolic problems, not as establishing it^[1]. PWS also is not one uniform genotype. A deletion, a maternal uniparental disomy, and an imprinting defect can carry different clinical severity^[2], so a result in a patient with a 15q11.2-q13.1 deletion should not be assumed to generalize to every person with PWS.

Tirzepatide's own approval does not mention PWS. In the United States, Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults and children 10 and older with type 2 diabetes, and to reduce cardiovascular risk in adults with type 2 diabetes at high risk, dosed from a 2.5 mg weekly starting point up to a 15 mg maximum in adults^[4]. Zepbound, the same molecule, is approved separately for chronic weight management. Using it in a person with PWS is an off-label decision that belongs with a clinician who understands both the drug's gastrointestinal side-effect profile and the syndrome's baseline feeding and metabolic quirks.

What this means for patients and caregivers

If you are a caregiver or clinician managing someone with Prader-Willi syndrome and diabetes that has not responded to standard agents, this case report is a reason to raise tirzepatide as a question for the treating endocrinologist, not a reason to start it unsupervised. Our tirzepatide overview covers how the drug works and its documented side effects, and the regulatory status page covers where it is prescription-only. This article is educational and is not medical advice; anyone considering a change in a PWS treatment plan should talk to the clinicians already managing that patient's care.